来自肠道菌群的酸盐通过促进蛋白质化来加剧过敏性气道炎症
1Department of Pathogen Biology, College of Basic Medical Sciences, Jilin University, Changchun, 130021, China; The Medical Basic Research Innovation Center of Airway Disease in North China, Ministry of Education of China, China.
Redox biology
|April 2, 2025
概括
肠道细菌的代谢物,如酸盐,通过增加蛋白质化,加剧过敏呼吸道炎症 (AAI). 便微生物群移植 (FMT) 可以缓解AAI症状,提供新的治疗点.
科学领域:
- 免疫学 免疫学 免疫学
- 代谢学 代谢学 代谢学
- 微生物组研究的研究.
背景情况:
- 过敏呼吸道炎症 (AAI) 涉及免疫反应和代谢过程之间的复杂相互作用.
- 代谢失调和蛋白质翻译后修饰 (PTMs) 涉及疾病的发病.
- 肠道微生物群代谢物在AAI中的作用及其对PTM的影响仍未得到充分研究.
研究的目的:
- 研究肠道微生物群代谢物在AAI发展中的作用.
- 探索这些代谢物对AAI中蛋白质糖化的影响.
- 确定针对肠道微生物组的潜在治疗策略.
主要方法:
- 在AAI患者和小鼠中分析代谢物.
- 门德尔的随机化来评估苏克辛酸对喘的风险.
- 在体内使用AAI小鼠模型进行的实验研究,其中包括外源性糖酸盐和便微生物群移植 (FMT).
- 用BEAS-2B细胞进行了体外实验,以研究酸盐对蛋白质酸的作用.
主要成果:
- 苏酸盐被确定为AAI患者的关键代谢物,与免疫参数和IgE相关.
- 肠道细菌是AAI小鼠中酸盐升高的主要来源.
- 苏酸在小鼠中加剧了AAI,增加了呼吸道阻力和炎症.
- 在AAI小鼠肺部中观察到蛋白质化显著差异,其代谢途径发生了变化.
- 通过减少糖酸和蛋白质糖化,FMT减轻了AAI症状.
- 酸盐在体外促进了蛋白质化,SOD2被确定为关键的修饰蛋白质.
结论:
- 由肠道微生物群衍生出的酸盐通过增加肺蛋白化来加剧AAI.
- FMT可以逆转这些影响,表明其治疗潜力.
- 准糖酸代谢和蛋白质糖化为AAI提供了新的治疗途径.
相关概念视频
01:20Asthma: Pathogenesis and Management
263
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
263
02:06Allergic Reactions
27.2K
Overview
27.2K
01:26Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
186
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
186
01:27Allergic Drug Reactions
799
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
799
01:19Antiasthma Drugs: Leukotriene Modifiers
180
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
180